Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing (Contributions to Management Science)
Gerrit Reepmeyer
The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R and D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R and D managers with recommendations on how to conclude and manage this type of deals more effectively.
Categories:
Year:
2006
Edition:
1
Publisher:
Physica-Verlag HD
Language:
english
Pages:
306
ISBN 10:
3790816671
ISBN 13:
9783790816679
Series:
Contributions to Management Science
File:
PDF, 17.21 MB
IPFS:
,
english, 2006
This book isn't available for download due to the complaint of the copyright holder